These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22913714)

  • 41. Interactions between antifungal and antiretroviral agents.
    Hughes CA; Foisy M; Tseng A
    Expert Opin Drug Saf; 2010 Sep; 9(5):723-42. PubMed ID: 20345324
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety of posaconazole.
    Jacinto PL; Chandrasekar P
    Expert Opin Drug Saf; 2013 Mar; 12(2):265-74. PubMed ID: 23360443
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation.
    Groll AH; Castagnola E; Cesaro S; Dalle JH; Engelhard D; Hope W; Roilides E; Styczynski J; Warris A; Lehrnbecher T; ; ; ; ;
    Lancet Oncol; 2014 Jul; 15(8):e327-40. PubMed ID: 24988936
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Triazole antifungal agents drug-drug interactions involving hepatic cytochrome P450.
    Gubbins PO
    Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1411-29. PubMed ID: 21995615
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation.
    Amigues I; Cohen N; Chung D; Seo SK; Plescia C; Jakubowski A; Barker J; Papanicolaou GA
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):46-52. PubMed ID: 20053331
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A clinical cohort trial of antifungal combination therapy: efficacy and toxicity in haematological cancer patients.
    Rieger CT; Ostermann H; Kolb HJ; Fiegl M; Huppmann S; Morgenstern N; Tischer J
    Ann Hematol; 2008 Nov; 87(11):915-22. PubMed ID: 18641986
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Epidemiology and risk factors for invasive fungal diseases in hematopoietic stem cell transplantation.
    Girmenia C; Ferretti A; Barberi W
    Curr Opin Hematol; 2014 Nov; 21(6):459-65. PubMed ID: 25295743
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comedication of caspofungin acetate and cyclosporine A after allogeneic haematopoietic stem cell transplantation leads to negligible hepatotoxicity.
    Christopeit M; Eikam M; Behre G
    Mycoses; 2008; 51 Suppl 1():19-24. PubMed ID: 18471157
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Therapy of severe fungal infections].
    Battegay M; Flückiger U
    Internist (Berl); 2003 Dec; 44(12):1549-56. PubMed ID: 14689198
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Optimal use of the newer antifungal agents.
    Helwick C
    Oncology (Williston Park); 2000 Sep; 14(9):1262-4. PubMed ID: 11033823
    [No Abstract]   [Full Text] [Related]  

  • 51. New facets of antifungal therapy.
    Chang YL; Yu SJ; Heitman J; Wellington M; Chen YL
    Virulence; 2017 Feb; 8(2):222-236. PubMed ID: 27820668
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pseudomembranous tracheobronchitis caused by Rhizopus sp. After allogeneic stem cell transplantation.
    Williams KE; Parish JM; Lyng PJ; Viggiano RW; Wesselius LJ; Ocal IT; Vikram HR
    J Bronchology Interv Pulmonol; 2014 Apr; 21(2):166-9. PubMed ID: 24739694
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinically relevant drug-drug interactions between antiretrovirals and antifungals.
    Vadlapatla RK; Patel M; Paturi DK; Pal D; Mitra AK
    Expert Opin Drug Metab Toxicol; 2014 Apr; 10(4):561-80. PubMed ID: 24521092
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Candida Parapsilosis in peripheral blood.
    Arora N; Parihar M; Mishra D; Bhattacharya S; Chakrapani A
    Indian J Pathol Microbiol; 2014; 57(4):645. PubMed ID: 25308031
    [No Abstract]   [Full Text] [Related]  

  • 55. Current concepts in antifungal pharmacology.
    Lewis RE
    Mayo Clin Proc; 2011 Aug; 86(8):805-17. PubMed ID: 21803962
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antifungal attributes of immunosuppressive agents: new paradigms in management and elucidating the pathophysiologic basis of opportunistic mycoses in organ transplant recipients.
    Singh N; Heitman J
    Transplantation; 2004 Mar; 77(6):795-800. PubMed ID: 15077015
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Clinical usefulness of triazole derivatives in the management of fungal infections].
    Carrillo-Muñoz AJ; Giusiano G; Arechavala A; Tur-Tur C; Eraso E; Jauregizar N; Quindós G; Negroni R
    Rev Esp Quimioter; 2015 Aug; 28(4):169-82. PubMed ID: 26200025
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications.
    Nett JE; Andes DR
    Infect Dis Clin North Am; 2016 Mar; 30(1):51-83. PubMed ID: 26739608
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antifungal agents and the kidney: pharmacokinetics, clinical nephrotoxicity, and interactions.
    Tragiannidis A; Gkampeta A; Vousvouki M; Vasileiou E; Groll AH
    Expert Opin Drug Saf; 2021 Sep; 20(9):1061-1074. PubMed ID: 33896310
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Overview of Treatment Approaches for Fungal Infections.
    Carmona EM; Limper AH
    Clin Chest Med; 2017 Sep; 38(3):393-402. PubMed ID: 28797484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.